Temporal trends in guideline‐recommended cardiometabolic testing completeness before initiating immune checkpoint inhibitors: A cohort study-Reference-Cited by-同舟云学术

Temporal trends in guideline‐recommended cardiometabolic testing completeness before initiating immune checkpoint inhibitors: A cohort study

Published:2023-11-27 Issue: Volume: Page:
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Chan Jeffrey Shi Kai¹^ORCID,Chou Oscar Hou In¹^ORCID,Lee Teddy Tai Loy¹^ORCID,Lee Yan Hiu Athena¹^ORCID,Chan Raymond Ngai Chiu¹^ORCID,Dee Edward Christopher²^ORCID,Ng Kenrick³^ORCID,Liu Tong⁴^ORCID,Tse Gary⁴⁵⁶^ORCID

Affiliation:

1. Cardio‐Oncology Research Unit Cardiovascular Analytics Group PowerHealth Research Institute Hong Kong China

2. Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA

3. Department of Medical Oncology University College London Hospitals NHS Foundation Trust London UK

4. Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China

5. Kent and Medway Medical School University of Kent and Canterbury Christ Church University Canterbury Kent UK

6. School of Nursing and Health Studies Hong Kong Metropolitan University Hong Kong China

Funder

Hong Kong Metropolitan University

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13754

Reference10 articles.

1. Cardiovascular Toxicities of Immune Checkpoint Inhibitors

2. Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-based Study

3. Immune checkpoint inhibitors – the revolutionary cancer immunotherapy comes with a cardiotoxic price

4. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

5. European Society of Cardiology quality indicators for the prevention and management of cancer therapy‐related cardiovascular toxicity in cancer treatment;Lee GA;Eur Hear J – Qual Care Clin Outcomes.,2023